Summary
0J9P Chart
Incyte: New CEO Brings A New Possible Outcome
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Jakafi delivering $709M in Q1 2025 and strong growth across indications. Q1 2025 revenue grew 20% year-over-year to $1.05B, prompting management to raise full-year guidance, reflecting confidence in core products.
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
FDA Extends INCY's Application for Opzelura Label Expansion
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
Incyte Corporation Dividends
Incyte Corporation Earnings
| 29 Jul 2025 (In 3 weeks) Date | | 1.4 Cons. EPS | - EPS |
| 28 Jul 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | - Cons. EPS | 1.02 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.54 EPS |
| 29 Jul 2025 (In 3 weeks) Date | | 1.4 Cons. EPS | - EPS |
| 28 Jul 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 11 Feb 2025 Date | | - Cons. EPS | 1.02 EPS |
| 29 Oct 2024 Date | | - Cons. EPS | 0.54 EPS |
Incyte Corporation (0J9P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Incyte Corporation ever had a stock split?
Incyte Corporation Profile
| Biotechnology Industry | Healthcare Sector | Herve Hoppenot CEO | LSE Exchange | US45337C1027 ISIN |
| US Country | 2,617 Employees | - Last Dividend | 1 Sep 2000 Last Split | 4 Nov 1993 IPO Date |
Overview
Incyte Corporation is a prominent biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. With a broad interest in hematology/oncology and inflammation and autoimmunity sectors, Incyte operates both within the United States and on an international scale. Originally founded in 1991 and known as Incyte Genomics Inc., the company underwent a name change to Incyte Corporation in March 2003. It has established a formidable presence in the pharmaceutical industry, not only through the inception of proprietary drugs but also via strategic collaborations and in-license agreements with other leading biotech entities such as Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited. Headquartered in Wilmington, Delaware, Incyte holds a pivotal role in pushing forward the boundaries of medical research and patient care in critical disease areas.
Products and Services
- JAKAFI (ruxolitinib)
A cornerstone in Incyte's portfolio, JAKAFI is approved for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Its mechanism targets aberrant signaling pathways to curb disease progression.
- MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)
Designed for patients with relapsed or refractory diffuse large B-cell lymphoma; a testament to Incyte's commitment to addressing unmet needs in oncology.
- PEMAZYRE (pemigatinib)
Acts as a fibroblast growth factor receptor kinase inhibitor, targeting oncogenic drivers in various liquid and solid tumor types, showcasing Incyte's innovative approach in targeted cancer therapy.
- ICLUSIG (ponatinib)
Approved for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, providing a targeted therapeutic option for these hematologic cancers.
- ZYNYZ (retifanlimab-dlwr)
This drug is deployed in the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma, underscoring the company's dedication to rare oncology indications.
- OPZELURA cream
Marketed for the treatment of atopic dermatitis, this offering diversifies Incyte's portfolio into the dermatological field, addressing a common yet challenging chronic skin condition.
In addition to these marketed products, Incyte's clinical stage pipeline showcases a robust commitment to innovation through a variety of compounds under development, including retifanlimab for additional cancers, axatilimab for chronic GVHD, and a range of molecules designed to tackle solid tumors. The depth and breadth of Incyte's clinical research reflect its continuous pursuit of therapeutic advances to improve patient outcomes in areas of significant unmet medical need.
Contact Information
